Probiotics and inflammatory bowel disease

BioDrugs

Volumn 17, Issue 3, 2003, Pages 179-186

  Kwon, John H ^a   Farrell, Richard J ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; IMMUNOMODULATING AGENT; MESALAZINE; MUTAFLOR; PROBIOTIC AGENT;

ABDOMINAL PAIN; BACTERIAL COLONIZATION; BACTERIAL STRAIN; CLINICAL TRIAL; DIARRHEA; DRUG TOLERANCE; ENTERITIS; GENETIC ANALYSIS; HEADACHE; HUMAN; INTESTINE FLORA; NAUSEA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; YEAST;

ANIMALS; DISEASE MODELS, ANIMAL; ESCHERICHIA COLI; HUMANS; INFLAMMATORY BOWEL DISEASES; LACTOBACILLUS; PROBIOTICS; SACCHAROMYCES;

EID: 0037945193     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200317030-00004     Document Type: Review

References (70)

1. Donowitz M. The burden of gastrointestinal diseases. Bethesda: American Gastroenterological Association, 2001: 30-40
2. Farrell RJ, Banerjee S, Peppercorn MA. Recent advances in inflammatory bowel disease. Crit Rev Clin Lab Sci 2001; 38: 33-108
3. Taylor KD, Plevy SE, Yang H, et al. ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease. Gastroenterology 2001; 120: 1347-55
4. Lilly DM, Stillwell RH. Probiotics: growth promoting factors produced by microorganisms. Science 1965; 47: 747-8
5. Elmer GW, Surawicz CM, McFarland LV. Biotherapeutic agents: a neglected modality for the treatment and prevention of selected intestinal and vaginal infections. JAMA 1996; 275: 870-6
6. Bennet JD, Brinkman M. Treatment of ulcerative colitis by implantation of normal colonic flora [letter]. Lancet 1989; I: 164
7. Shanahan F. Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics. Gastroenterology 2001; 120: 622-35
8. Slezak M. Emerging treatments for IBD. Gastroenterology and Endoscopy News Oct 2001; 53 (10): 1-8
9. Farrell RJ, LaMont JT. Microbial factors in inflammatory bowel disease. Gastroenterol Clin North Am 2002; 31: 41-62
10. Duchmann R, Kaiser I, Hermann E, et al. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol 1995; 102: 448-55
11. Sartor RB. Enteric microflora in IBD: pathogens or commensals? Inflamm Bowel Dis 1997; 3: 230-5
12. Rutgeerts P, Goboes K, Peeters M, et al. Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet 1991; 338: 771-4
13. Sandborn WJ, Landers CJ, Tremaine WJ, et al. Antineutrophil cytoplasmic antibody correlates with chronic pouchitis after ileal pouch-anal anastomosis. Am J Gastroenterol 1995; 90: 740-7
14. D'Haens GR, Geboes K, Peeters M, et al. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998; 114: 262-7
15. Harper PH, Lee EC, Kettlewell MG, et al. Role of the faecal stream in the maintenance of Crohn's colitis. Gut 1985; 26: 279-84
16. Sartor RB. Microbial factors in the pathogenesis of Crohn's disease, ulcerative colitis, and experimental intestinal inflammation. In: Kirsner JB, editor. Inflammatory bowel disease. Philadelphia: WB Saunders, 2000: 153-178
17. Shanahan F. Probiotics in inflamatory bowel disease. Gut 2001; 48: 609
18. Swidsinski A, Ladhoff A, Pernthaler A, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology 2002; 122: 44-54
19. Giaffer MH, Holdsworth CD, Duerden BI. Virulence properties of Escherichia coli strains isolated from patients with inflammatory bowel disease. Gut 1992; 33: 646-50
20. Giaffer MH, Holdsworth CD, Duerden BI. The assessment of faecal flora in patients with inflammatory bowel disease by a simplified bacteriological technique. J Med Microbiol 1991; 35: 238-43
21. Favier C, Neut C, Mizon C, et al. Fecal beta-D-galactosidase production and Bifidobacteria are decreased in Crohn's disease. Dig Dis Sci 1997; 42: 817-22
22. Walmsley RS, Anthony A, Sim R, et al. Absence of Escherichia coli, Listeria monocytogenes, and Klebsiella pneumoniae antigens within inflammatory bowel disease tissues. J Clin Pathol 1998; 51: 657-61
23. Kennedy RJ, Kirk SJ, Gardiner KR. Promotion of a favorable gut flora in inflammatory bowel disease. JPEN J Parenter Enteral Nutr 2000; 24: 189-95
24. Burke DA, Axon AT. Adhesive Escherichia coli in inflammatory bowel disease and infective diarrhoea. BMJ 1988; 297: 102-4
25. Vandenbergh PA. Lactic acid bacteria, their metabolic products and interference with microbial growth. FEMS Microbio Rev 1993; 12: 221-38
26. Rath HC, Herfarth HH, Ikeda JS, et al. Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta2 microglobulin transgenic rats. J Clin Invest 1996; 98: 945-53
27. Contractor NV, Bassiri H, Reya T, et al. Lymphoid hyperplasia, autoimmunity, and compromised intestinal intraepithelial lymphocyte development in colitis-free gnotobiotic IL-2-deficient mice. J Immunol 1998; 160: 385-94
28. Dianda L, Hanby AM, Wright NA, et al. T cell receptor-alpha beta-deficient mice fail to develop colitis in the absence of a microbial environment. Am J Pathol 1997; 150: 91-7
29. Sellon RK, Tonkonogy S, Schultz M, et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun 1998; 66: 5224-31
30. Madsen KL, Doyle JS, Jewell LD, et al. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology 1999; 116: 1107-14
31. Schultz M, Veltkamp C, Dieleman LA, et al. Continuous feeding of Lactobacillus plantarum attenuates established colitis in interleukin-10 deficient mice [abstract]. Gastroenterology 1998; 114: A4426
32. Kennedy RJ, Hoper M, Weir H, et al. Probiotic therapy stabilizes the gut mucosal barrier in the interleukin 10 knockout model of colitis [abstract]. Br J Surg 2000; 87: 669
33. Hampe J, Cuthbert A, Croucher PJ, et al. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet 2001; 357: 1925-8
34. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411: 599-603
35. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001; 411: 603-6
36. Malin M, Suomalainen H, Saxelin M, et al. Promotion of IgA immune response in patients with Crohn's disease by oral bacteriotherapy with Lactobacillus GG. Ann Nutr Metab 1996; 40: 137-45
37. Campieri M, Gionchetti P. Probiotics in inflammatory bowel disease: new insight to pathogenesis or a possible therapeutic alternative? Gastroenterology 1999; 116: 1246-9
38. Shanahan F. Probiotics and inflammatory bowel disease: is there a scientific rationale? Inflamm Bowel Dis 2000; 6: 107-15
39. Bengmark S. Ecological control of the gastrointestinal tract: the role of probiotic flora. Gut 1998; 42: 2-7
40. Gordon JI, Hooper LV, McNevin MS, et al. Epithelial cell growth and differentiation: III. promoting diversity in the intestine: conversations between the microflora, epithelium, and diffuse GALT. Am J Physiol 1997; 273: G565-70
41. Mourelle M, Salas A, Guarner F, et al. Stimulation of transforming growth factor beta1 by enteric bacteria in the pathogenesis of rat intestinal fibrosis. Gastroenterology 1998; 114: 519-26
42. Hamilton-Miller JMT. A review of clinical trials of probiotics in the management of inflammatory bowel disease. Infect Dis Res 2001; 3: 83-87
43. Gupta P, Andrew H, Kirschner BS, et al. Is lactobacillus GG helpful in children with Crohn's disease?: results of a preliminary, open-label study. J Pediatr Gastroenterol Nutr 2000; 31: 453-7
44. Guslandi M, Mezzi G, Sorghi M, et al. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 2000; 45: 1462-4
45. Malchow HA. Crohn's disease and Escherichia coli: a new approach in therapy to maintain remission of colonic Crohn's disease? J Clin Gastroenterol 1997; 25: 653-8
46. Rembacken BJ, Snelling AM, Hawkey PM, et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999; 354: 635-9
47. Kruis W, Schutz E, Fric P, et al. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997; 11: 853-8
48. Venturi A, Gionchetti P, Rizzello F, et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 1999; 13: 1103-8
49. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119: 305-9
50. Nissle A. Ubersicht uber die bedeutung bakeriologischer stuhluntersuchgen beinichtinfektiosen darmerkrankungen. Arch Hyg Bakteriol 1930; 103: 124-31
51. Nissle A. Das problem der dysbakterie des dickdarms und ihrer behandlung. Klin Wochenschr 1932; 13: 1456-9
52. McCann ML, Abrams RS, Nelson Jr RP. Recolonization therapy with nonadhesive Escherichia coli for treatment of inflammatory bowel disease. Ann N Y Acad Sci 1994; 730: 243-5
53. Blum G, Marre R, Hacker J. Properties of Escherichia coli strains of serotype O6. Infection 1995; 23: 234-6
54. Arvola T, Laiho K, Torkkeli S, et al. Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhea in children with respiratory infections: a randomized study [abstract]. Pediatrics 1999; 104: e64
55. Biller JA, Katz AJ, Flores AF, et al. Treatment of recurrent Clostridium difficile colitis with Lactobacillus GG. J Pediatr Gastroenterol Nutr 1995; 21: 224-6
56. Hilton E, Kolakowski P, Smith M, et al. Efficacy of Lactobacillus GG as a diarheal preventative in travelers diarrhea. J Travel Med 1996; 4: 41-3
57. Oksanen PJ, Salminen S, Saxelin M, et al. Prevention of travellers diarrhoea by Lactobacillus GG. Ann Med 1990; 22: 53-6
58. Alander M, Satokari R, Korpela R, et al. Persistence of colonization of human colonic mucosa by a probiotic strain, Lactobacillus rhamnosus GG, after oral consumption. Appl Environ Microbiol 1999; 65: 351-4
59. Bernet MF, Brassart D, Neeser JR, et al. Lactobacillus acidophilus LA 1 binds to cultured human intestinal cell lines and inhibits cell attachment and cell invasion by enterovirulent bacteria. Gut 1994; 35: 483-9
60. Silva M, Jacobus NV, Deneke C, et al. Antimicrobial substance from a human Lactobacillus strain. Antimicrob Agents Chemother 1987; 31: 1231-3
61. Dias RS, Bambirra EA, Silva ME, et al. Protective effect of Saccharomyces boulardii against the cholera toxin in rats. Braz J Med Biol Res 1995; 28: 323-5
62. Castagliuolo I, Riegler MF, Valenick L, et al. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infect Immun 1999; 67: 302-7
63. Bleichner G, Blehaut H, Mentec H, et al. Saccharomyces boulardii prevents diarrhea in critically ill tube-fed patients: A multicenter, randomized, double-blind placebo-controlled trial. Intensive Care Med 1997; 23: 517-23
64. McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994; 271: 1913-8
65. Plein K, Hotz J. Therapeutic effects of Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn's disease with special respect to chronic diarrhea: a pilot study. Z Gastroenterol 1993; 31: 129-34
66. Hamilton-Miller JMT, Gibson GR. Efficacy studies of probiotics: a call for guidelines. Br J Nutr 1999; 82: 73-5
67. Kimmey MB, Elmer GW, Surawicz CM, et al. Prevention of further recurrences of Clostridium difficile colitis with Saccharomyces boulardii. Dig Dis Sci 1990; 35: 897-901
68. Lee YK, Salminen S. The coming of age of probiotics. Trends Food Sci Tech 1995; 6: 241-5
69. Katz JA, Pirovano F, Matteuzzi D, et al. Commercially available probiotic preparations: are you getting what you pay for? [abstract]. Gastroenterology 2002; 122: A459
70. Steidler L, Hans W, Schotte L, et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 2000; 289: 1352-5